Legislative Successes

IFFGD PRESENTS SENATOR BALDWIN WITH 2019 DDNC DISTINGUISHED PUBLIC SERVICE AWARD From introducing multiple statements in the Senate recognizing Gastroparesis Awareness Month to leading a resolution in the House to raise awareness of functional gastrointestinal (GI) and motility disorders, Senator Tammy Baldwin (WI) has been a constant champion for the digestive health community during her time […]

Written Comments to FDA December 30, 2019

The following written comments were submitted to the Dockets Management Staff (HFA-305) Food and Drug Administration by IFFGD President, Ceciel T. Rooker, in response to Docket No. FDA-2019-D-4247 on December 30, 2019.     Thank you for your leadership at the Center for Drug Evaluation and Research in the Food and Drug Administration (FDA). The International Foundation for […]

Written Comments to FDA October 15, 2019

The following written comments were submitted to the Dockets Management Staff (HFA-305) Food and Drug Administration by IFFGD President, Ceciel T. Rooker, in response to Docket No. FDA-2015-D-2479 on October 15, 2019.     Thank you for your leadership at the Office of Policy in the Food and Drug Administration (FDA). The International Foundation for Gastrointestinal Disorders (IFFGD) […]

Written Comments to SSA September 23, 2019

The following written comments were submitted to the Office of Disability Policy of the Social Security Administration (SSA) by IFFGD President, Ceciel T. Rooker, in response to Docket No. SSA-2017-0042 on September 23, 2019.     Thank you for your leadership at the Office of Disability Policy. The International Foundation for Gastrointestinal Disorders (IFFGD) is grateful for the […]

Written comments to FDA April 30, 2019

The following written comments were submitted to the Dockets Management Staff (HFA-305) Food and Drug Administration by IFFGD President, Ceciel T. Rooker, in response to Docket No. FDA-2019-N-0077 on April 30, 2019.     SUMMARY   On behalf of the millions of Americans living with a rare gastrointestinal (GI) illness, the International Foundation for Gastrointestinal Disorders (IFFGD) thanks […]

FISCAL YEAR 2020

IFFGD President, Ceciel Rooker, submitted the following written statement to the House and Senate Committee on Appropriations, Subcommittee on Labor, Health and Human Services, Education, and Related Agencies regarding Fiscal Year (FY) 2020 appropriations for medical research and public health programs. April 9, 2019       STATEMENT OF CECIEL T. ROOKER PRESIDENT INTERNATIONAL FOUNDATION FOR […]

Written Comments to SSA February 15, 2019

The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Social Security Administration (SSA) in response to Docket No. SSA-2018-0017 calling for public comments regarding the “Consideration of Pain in the Disability Determination Process.”  On behalf of the millions of Americans living with a chronic, and often painful, gastrointestinal (GI) […]

Written Comments to HHS February 5, 2019

The following comments were submitted by IFFGD President, Ceciel T. Rooker, to the US Department of Health and Human Services (HHS) in regards to Docket No. HHS-OS-2018-0027, “Request for Public Comments on the Pain Management Best Practices Inter-Agency Task Force Draft Report on Pain Managementn Best Practices: Updates, Gaps, Inconsistencies, and Recommendations.” On behalf of […]

Written Comments to DoD December 13, 2018

The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Department of Defense (DoD) in connection with a January 10, 2019 meeting of the TRICARE Beneficiary Advisory Panel (BAP) regarding the Uniform Formulary and, specifically, review of gastrointestinal agents: The International Foundation for Gastrointestinal Disorders (IFFGD) commends TRICARE and the […]

Written Comments to FDA October 18, 2018

  The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Food and Drug Administration (FDA) in connection with a October 18, 2018 joint meeting of the FDA Gastrointestinal Drugs Advisory Committee and Risk Management Advisory Committee to discuss the reintroduction of Zelnorm: The International Foundation for Gastrointestinal Disorders (IFFGD) […]

Written Comments to FDA October 17, 2018

The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Food and Drug Administration (FDA) in connection with a October 17, 2018 joint meeting of the FDA Gastrointestinal Drugs Advisory Committee to discuss approval of prucalopride: The International Foundation for Gastrointestinal Disorders (IFFGD) commends the FDA on its commitment to […]

FISCAL YEAR 2019

IFFGD President, Ceciel Rooker, submitted the following written statement to the House and Senate Committees on Appropriations, Subcommittees on Labor, Health and Human Services, Education, and Related Agencies regarding Fiscal Year (FY) 2019 appropriations for medical research and public health programs at the National Institutes of Health (NIH) and related agencies on June 1, 2018: […]